UnitedHealth stock shows mixed short-term performance but strong long-term gains. UBS raised its price target to $460 with a Buy rating, and Goldman Sachs added UNH to its Conviction List. However, Berkshire Hathaway exited its stake, signaling a shift away from healthcare. The company faces regulatory headwinds from potential Medicare Advantage overpayments of $7 billion annually, but is adopting AI tools to drive a turnaround.